| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 6.41 | 24.5% | 5.5% |
| Total Income | 6.41 | 24.5% | 5.5% |
| Expenditure | 10.31 | 3.3% | 10.5% |
| PBT | -1.97 | 64.3% | 63.5% |
| Net Profit | -1.95 | 64.4% | 63.9% |
| OPM | -60.74% | 32.89pp | 9.05pp |
| NPM | -30.32% | 49.29pp | |
| EPS | -0.07 | 77.4% | 85.7% |
Vivos Therapeutics Reports Q3 2026 Financial Results and Operational Update
17 Nov 2026 · 17 Nov, 4:39 pm
Summary
Vivos Therapeutics reported third quarter 2026 revenue of $6.4 million, a 24% increase quarter-over-quarter, and $16.7 million for the nine months ended September 30, 2026, up from $13.6 million in the prior year period. The company's operating loss improved by 18% year-over-year to $3.9 million in Q3 2026, driven by a 17% reduction in operating expenses. Management highlighted decisive steps taken to reduce costs and strengthen the balance sheet, including eliminating an estimated $5 million in annual operating costs and exchanging senior secured debt for equity.
Key Highlights
- 1
Revenue was $6.4 million for the third quarter of 2026, up 24% from $5.2 million in the second quarter of 2026.
- 2
For the nine months ended September 30, 2026, revenue was $16.7 million compared to $13.6 million for the same period in 2025.
- 3
Gross margin was 52% in the third quarter of 2026 compared to 58% in the third quarter of 2025.
- 4
Operating expenses for the third quarter ended September 30, 2026, decreased by 17% to $7.2 million compared to $8.7 million in the same period a year ago.
- 5
The third quarter 2026 operating loss improved 18% to $3.9 million, compared to $4.7 million in the third quarter of 2025.
- 6
Net loss for the third quarter of 2026 was $2.0 million, compared to $5.4 million in the third quarter of 2025.
- 7
At September 30, 2026, cash and cash equivalents were $0.2 million and total stockholders' equity was $2.4 million.
Management Comments
Kirk Huntsman
During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway. We also exchanged approximately $6.1 million of senior secured debt for equity during 2026 and, following the closing of our SOD Sciences transaction in October, regained compliance with Nasdaq’s stockholders’ equity requirement. We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.
Informational and educational content only. Not investment advice.